Welcome, Guest. Please login or register.
March 29, 2024, 09:06:44 am

Login with username, password and session length


Members
  • Total Members: 37614
  • Latest: bondann
Stats
  • Total Posts: 772954
  • Total Topics: 66311
  • Online Today: 741
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 2
Guests: 445
Total: 447

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: dendritic cell-based vaccine for treating HIV infection french tested in brazil  (Read 8421 times)

0 Members and 1 Guest are viewing this topic.

Offline bimazek

  • Member
  • Posts: 781
A dendritic cell-based vaccine for treating HIV infection: background and preliminary results

i have wanted to post on this for a year... read the links and the highlights below...

http://www.blackwell-synergy.com/doi/abs/10.1111/j.1365-2796.2006.01738.x
February 2007

 our therapeutic vaccine should next be tested on patients who are resistant to ART as well as on the large number who would like to stop ART.

JM Andrieu, W Lu - Journal of Internal Medicine, 2007 - Blackwell Synergy
... 1 Zinkernagel RM. Immunity, immunopathology and vaccines against HIV? Vaccine 2002;
20: 1913–7. 2 Centers for Disease Control and Prevention (CDC). ...

A year following vaccination, 8 patients had a plasma viral load decrease >90%; among them, 4 had viral load <1000 copies mL-1. Moreover, by one year, the viral load decline of the 18 patients was significantly correlated with their percentage of HIV-1-gag-specific CD8+ T cells expressing perforin and that of HIV-1-specific CD4+ TH1 cells. This is the first demonstration of the capacity of a therapeutic vaccine to induce an effective HIV-specific T cell response associated with sustained viral suppression in untreated viremic patients. The manipulation of antigen presenting cells to elicit virus-specific cellular responses is a promising tool to control persistant viral infections.

I have wanted to post on this for a year DC vaccines but this new new article is very interesting

good responses

a gay pdD guy i talked to online said he feels dendritic cell vaccines are going to be a big growth area and such

there is so much good stuff in this long article...

http://www.blackwell-synergy.com/action/showFullText?submitFullText=Full+Text+HTML&doi=10.1111%2Fj.1365-2796.2006.01738.x


HIV-1 is now more and more frequently viewed as a poorly cytopathic virus by many immunologists

The administration of an efficient therapeutic vaccine (probably to be repeated every year or every 2 years) to HIV-infected patients should (if successful) lead to a decrease in viral replication and release. This would result in the stabilization/partial reconstitution of the immune system allowing vaccinated patients to avoid or postpone ARTs

Four months after the first vaccination, the median PVL of the 18 patients decreased by 80% (P < 0.01) and their CD4 lymphocytes count stabilized. A year after the first vaccination, viral concentration decreased by more than 90% in 8 of the 18 patients.


Transient viral infections caused by cytopathic viruses like smallpox or poliomyelitis

Persistent viral infections like the herpes simplex 1 and 2 (HHV1 and 2) or the varicella/zoster virus (HHV3) infections are caused by intermittent cytopathic viruses. After the primary infection, the replication of these viruses inside their target cells is strongly controlled by the permanent pressure of specific T cells which maintain them in a so-called state of latency. In fact, as soon as there is a transient or more prolonged weakness, disturbance or loss of anti-viral immune functions (whether provoked by ageing, immunosuppressive therapies or immunosuppressive infections), these viruses resume their replication with their associated cytopathic effects (before being controlled again or not depending on the level of impairment of the immune system).

Persistent viral infections caused by poorly/noncytopathic viruses include two devastating viruses: the hepatitis B virus (HBV) and the hepatitis C virus (HCV). The immune system exerts a strong control on viral replication in the majority of individuals who have acquired HBV. However, it is not effective enough in a minority of them and in almost all patients with HCV with the consequence that the viral replication in infected cells and measurable viral release in the extracellular milieu persist for life. This is also the case of the human immunodeficiency virus -1 (HIV-1) which is now more and more frequently viewed as a poorly cytopathic virus by many immunologists [1], although it has been considered for a long time as a cytopathic virus by virologists. Importantly, cellular damages provoked by these three persistent infections do not directly result from viral replication but from immunopathology associated with the chronic release of the virus and inadequate response of the immune system

Offline ronaldinho

  • Member
  • Posts: 79
18 people is too small a sample. Besides, there is no control group, which makes any "scientific" conclusion impossible.

The second phase of this study was scheduled to begin in april 2007, with 40 volunteers, this time not only from Brazil, but from also from France, Belgium and the USA. The aim now would be to standardize the dosage and higher the potence of the treatment..Still no news from this second phase, which should take up to 2 years to be concluded.
I cannot understand, if results from the first phase of the study in 2004 were so astounding as it seems, why the second phase of the study began only in 2007??
The brazilian responsible for conducting the trials in Brazil (Mr. Luiz Cláudio Arraes) said that the production of the vaccine in commercial scale is still unthinkable due to the high costs of the logisticc involved , and that the final phase of this study would still take something between 7 and 10 years. They classify the study as "promising". In a piece of news from last week the brazilian researcher said that the study was halted in 2004 due to lack of funding (?!). It also says that have only 7 volunteers at the moment aand are still recruiting. It also says that the french researchers are no longer in the study. This is all very strange.

« Last Edit: September 24, 2007, 02:52:11 pm by ronaldinho »

Offline ronaldinho

  • Member
  • Posts: 79
http://www.arcat-sante.org/actus/109/Vaccin_therapeutique_retour_sur_un_effet_d_annonce

Do not want to sound downbeat, but if anybody can read french, the link above can be useful in terms of putting the study conducted in Brazil in 2004 in a more realistic perspective.

Offline Ann

  • Administrator
  • Member
  • Posts: 28,134
  • It just is, OK?
    • Num is sum qui mentiar tibi?
Hi Ron,

Don't worry about sounding "downbeat". If this vaccine isn't realistically going to be anywhere near ready for what sounds like as many as 15 years, then we need to be aware of that and not get hopes up.

I like my hopes to be tempered with realism.

And at times like these, I wish I could do the French thing.

Ann
Condoms are a girl's best friend

Condom and Lube Info  

"...health will finally be seen not as a blessing to be wished for, but as a human right to be fought for." Kofi Annan

Nymphomaniac: a woman as obsessed with sex as an average man. Mignon McLaughlin

HIV is certainly character-building. It's made me see all of the shallow things we cling to, like ego and vanity. Of course, I'd rather have a few more T-cells and a little less character. Randy Shilts

Offline newt

  • Member
  • Posts: 3,900
  • the one and original newt
This report covers the key parts of the French one (pls ignore the sub-ed's title "Human Test: Novel Vaccine Stops HIV" and naff opening para.

The essentials:

"Wei Lu, Jean-Marie Andrieu, and colleagues at the University of Paris in France and Pernambuco Federal University in Recife, Brazil, tested the vaccine on 18 Brazilian patients. All had HIV infection for at least a year. Their T-cell counts -- a crucial measure of AIDS progression -- were dropping, meaning their disease was worsening. None was taking anti-HIV medications.

"After getting three under-the-skin injections of the tailor-made vaccine, the amount of HIV in the patients' blood (called the viral load) dropped by 80%. After a year, eight of the 18 patients still had a 90% drop in HIV levels. All patients' T-cell counts stopped dropping.

Results published in Nature mag...

bit later Andrieu is reported as saying:

"'The results suggest that [these] vaccines could be a promising strategy for treating people with chronic HIV infection,' Andrieu and colleagues write. 'The significant decrease of viral load as well as maintenance of ... [T-]cell counts observed at one year after immunization are particularly promising.'"

Promising, proof of concept, come back in 5 years (hope and realism in equal measure me...)

- matt
"The object is to be a well patient, not a good patient"

Offline Jake72

  • Member
  • Posts: 145
The French article does reiterate what we've read in the English press release but warns that the announcement was premature, as the vaccine was tested on too few people and and that, in order to be valid, it would require a randomized trial with an appropriate control group. 

The article also heavily criticizes Dr. Andrieu for having stated something to the effect that four of the patients saw their viral loads drop to below 1,000 copies/ml, which made them "in principle, not contagious" because this false assertion could lead cause people to have unprotected sex.  The TRT-5 (a group of therapeutic research and treatment associations) has condemned what its members see as "irresponsible media and a guilty scientist"-Dr. Andrieu-because the safety and effectiveness of the vaccine have not yet been proven and because one of the basic principles of medical ethics-not to do harm-was not followed in this instance.  They reiterate that "so far, no vaccine has been able to prevent or to treat HIV infection.  The only proven means of preventing the sexual transmission of HIV has been the condom, male or female." 
« Last Edit: September 24, 2007, 06:42:51 pm by Jake72 »

Offline milker

  • Member
  • Posts: 4,034
  • Protected phone sex
That's odd I thought I posted the translation already.

/edited to remove the translation and add:/ never mind newt&jake already posted the gist of it.
« Last Edit: September 24, 2007, 07:17:00 pm by milker »
mid-dec: stupid ass
mid-jan: seroconversion
mid-feb: poz
mar 07: cd4 432 (35%) vl 54000
may 07: cd4 399 (28%) vl 27760
jul 07: cd4 403 (26%) vl 99241
oct 07: cd4 353 (24%) vl 29993
jan 08: cd4 332 (26%) vl 33308
mar 08: cd4 392 (23%) vl 75548
jun 08: cd4 325 (27%) vl 45880
oct 08: cd4 197 (20%) vl 154000 <== aids diagnosis
nov 2 08 start Atripla
nov 30 08: cd4 478 (23%) vl 1880 !!!!!!!!!!!!!!!!!!!!!!!!!!
feb 19 09: cd4 398 (24%) vl 430 getting there!
apr 23 09: cd4 604 (29%) vl 50 woohoo :D :D
jul 30 09: cd4 512 (29%) vl undetectable :D :D
may 27 10: cd4 655 (32%) vl undetectable :D :D

Now accepting applications from blowjob ninjas™

Offline milker

  • Member
  • Posts: 4,034
  • Protected phone sex
[double post]
damn timeouts
mid-dec: stupid ass
mid-jan: seroconversion
mid-feb: poz
mar 07: cd4 432 (35%) vl 54000
may 07: cd4 399 (28%) vl 27760
jul 07: cd4 403 (26%) vl 99241
oct 07: cd4 353 (24%) vl 29993
jan 08: cd4 332 (26%) vl 33308
mar 08: cd4 392 (23%) vl 75548
jun 08: cd4 325 (27%) vl 45880
oct 08: cd4 197 (20%) vl 154000 <== aids diagnosis
nov 2 08 start Atripla
nov 30 08: cd4 478 (23%) vl 1880 !!!!!!!!!!!!!!!!!!!!!!!!!!
feb 19 09: cd4 398 (24%) vl 430 getting there!
apr 23 09: cd4 604 (29%) vl 50 woohoo :D :D
jul 30 09: cd4 512 (29%) vl undetectable :D :D
may 27 10: cd4 655 (32%) vl undetectable :D :D

Now accepting applications from blowjob ninjas™

Offline Smoothstone

  • Member
  • Posts: 96
If money is an issue for developing this vaccine, hopefully the publication will attract investors. Perhaps some big pharma with mucho capital will buy the development rights and escalate the development process. The initial reports of small numbers benefiting are the magnets for the development money.  And, the publication of these early results may spur interest in this field.         

Side effects, known or emerging in the future, are major challenges for long term survival.  Immune stimulating treatments, without/minimal side effects, are attractive and hopeful to me.

Thanks for the info Biz. Hank
       


Offline hahaha

  • Member
  • Posts: 123
hook on clinicaltrial.gov and type
LC002,
this is the vaccine that you talk about.
Aug 9, 2006 Get infected in Japan #$%^*
Oct 2006 CD4 239
Nov 2006 CD4 299 VL 60,000
Dec 1, Sustiva, Ziagan and 3TC
Jan 07, CD4 400

Offline ronaldinho

  • Member
  • Posts: 79
hook on clinicaltrial.gov and type
LC002,
this is the vaccine that you talk about.

It is not the same vaccine. The french vaccine was custom-made for each person, based on dendritic cell extracted from the volunteers.It seems that the  chief researcher, Mr Jean Marie Andrieu, has a bad reputation for making public his "achievements" with little care to scientific rigour. He was involved in a similar case 2 decades ago, concerning a chemical named cyclosporine.

The fact that there was no follow-up study since 2004, that the french are no longer in the project and that no private company showed any interest in financing this french-brazilian vaccine says it all. Forget about this french/brazilian vaccine.

But in the site you mentioned, i have been able to identify two strials involving vaccines made based on the same method used in the french-brazilian vaccine.

http://clinicaltrial.gov/ct/show/NCT00510497;jsessionid=54C3D26142946BB6EA4C8B04E1FF0EC3?order=26

http://clinicaltrial.gov/ct/show/NCT00402142;jsessionid=54C3D26142946BB6EA4C8B04E1FF0EC3?order=10

Let us wait and see the results.
« Last Edit: September 26, 2007, 09:16:34 am by ronaldinho »

 


Terms of Membership for these forums
 

© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.